Oppenheimer analyst Suraj Kalia downgrades AtriCure (NASDAQ:ATRC) from Outperform to Perform.
Oppenheimer Downgrades AtriCure to Perform
Oppenheimer analyst Suraj Kalia downgrades AtriCure (NASDAQ:ATRC) from Outperform to Perform.
Related Posts
Sorrento Therapeutics Mexico To Partner With World Boxing Council For Screening Of COVID-19 Of All Convention Attendees with COVI-STIX At The 59th World Boxing Council Convention In Mexico City
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))) and the World Boxing Council ("WBC") announced today that Sorrento's COVI-STIX COVID-19 Virus Rapid Antigen Detection Test
Barclays Maintains Equal-Weight on Equitrans Midstream, Lowers Price Target to $8
Barclays analyst Marc Solecitto maintains Equitrans Midstream (NYSE:ETRN) with a Equal-Weight and lowers the price target from $9 to $8.
IntriCon Q2 EPS $(0.13) Misses $0.08 Estimate, Sales $30.20M Beat $28.56M Estimate
IntriCon (NASDAQ:IIN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $0.08 by 262.5 percent. This is a 550 percent decrease over losses of $(0.02) per share from the same